Protein / target
Small ribosomal subunit protein bS1
Protein at a glance
Biological role
Structural constituent of ribosome
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
Required for translation of most natural mRNAs except for leaderless mRNA.
View complete UniProt function annotationHide complete annotation
Required for translation of most natural mRNAs except for leaderless mRNA (PubMed:12068815, PubMed:17376482, PubMed:24339747, PubMed:7003157, PubMed:9677288). Binds mRNA upstream of the Shine-Dalgarno (SD) sequence and helps it bind to the 30S ribosomal subunit; acts as an RNA chaperone to unfold structured mRNA on the ribosome but is not essential for mRNAs with strong SDs and little 5'-UTR structure, thus it may help fine-tune which mRNAs that are translated (PubMed:24339747). Unwinds dsRNA by binding to transiently formed ssRNA regions; binds about 10 nucleotides (PubMed:22908248). Has a preference for polypyrimidine tracts (PubMed:778845). Negatively autoregulates its own translation (PubMed:2120211)
Subcellular location
Domains and Gene Ontology detail (18)Hide
Domains & features
Gene Ontology
- Ccytoplasm
- Ccytosolic small ribosomal subunit
- Cmembrane
- FmRNA binding
- FRNA binding
- Fsingle-stranded RNA binding
- Fstructural constituent of ribosome
- Pcytoplasmic translation
- Pnegative regulation of cytoplasmic translation
- Ppositive regulation of cytoplasmic translation
- Pribosomal small subunit assembly
- Ptranslation
Approved medicines with mapped indications
Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.
Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
Bacterial 70S ribosome inhibitor
Indicated for Bacterial Infections, Cystic Fibrosis, Eye Infections, HIV Infections
Bacterial 70S ribosome inhibitor
Indicated for Acne Vulgaris, Bacterial Infections, Brucellosis, Cholera
Bacterial 70S ribosome inhibitor
Indicated for Bacterial Infections, Eye Infections, Infections
Bacterial 70S ribosome inhibitor
Indicated for Bacterial Infections, Infections, Otitis Media, Pneumonia
Bacterial 70S ribosome inhibitor
Indicated for Acne Vulgaris, Bacterial Infections, Eye Infections, Infections
Bacterial 70S ribosome inhibitor
View all 11 targeting drugsHide
Bacterial 70S ribosome inhibitor
Indicated for Bacterial Infections, Eye Infections, Infections
Bacterial 70S ribosome inhibitor
Indicated for Bacteremia, Bacterial Infections, Infections, Osteomyelitis
Bacterial 70S ribosome inhibitor
Indicated for Skin Diseases, Bacterial, Soft Tissue Infections
Bacterial 70S ribosome inhibitor
Indicated for Bacterial Infections, Infections, Skin Diseases, Bacterial, Soft Tissue Infections
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
View all trials (26)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 6 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.
- Trial status changed
Doxycycline in Combination With Sitagliptin on the Glycemic and Cardiac Indices in Patients With Type 2 Diabetes Mellitus
- Trial status changed
Co-SAM: An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated Severe Acute Malnutrition
- Trial status changed
ORBS: Ocular Rosacea Biome Study
- Label change
Label change: DOXYCYCLINE (ANDA207289)
- Label change
Label change: LINEZOLID (ANDA206097)
- Label change
Label change: LINEZOLID (ANDA206097)
- Label change
Label change: DOXYCYCLINE (ANDA204234)
- New publicationA Phase 3 Study of the Safety and Efficacy of Tedizolid Phosphate in Patients <12 Years of Age With Acute Bacterial Skin and Skin Structure Infections.
- New publicationImpact of pneumococcal conjugate vaccines on invasive pneumococcal disease-causing lineages among South African children.
- New publicationGuidelines of care for the management of acne vulgaris.
- Safety communication
Drug Safety Update: Erythromycin: caution required due to cardiac risks (QT interval prolongation); drug interaction with rivaroxaban
- New publicationManagement of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.